Researcher Spotlight

“The inspiration for this project is in part our institutional experience with the combination of tafasitamab and lenalidomide, with Ohio State University contributing to both early clinical and preclinical work with this combination, and my experience caring for patients with relapsed Diffuse large B-cell lymphoma recognizing the limitations of our current standard of care treatments,”  says Dr. Bond.